[{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS411","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Xellsmart \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xellsmart \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : XS411 is an universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy being developed for the treatment of Parkinson's disease (PD).

                          Product Name : XS411

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 15, 2025

                          Lead Product(s) : XS411

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : According to the agreement, Orion has the right to develop and commercialize the drug precursor in its own territory. JMKX000623 is a potent and selective Nav1.8 blocker independently developed by Jemincare.

                          Product Name : JMKX000623

                          Product Type : Other Small Molecule

                          Upfront Cash : $16.1 million

                          June 05, 2022

                          Lead Product(s) : JMKX000623

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Orion Corporation

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.

                          Product Name : JMKX000623

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.8 million

                          June 05, 2022

                          Lead Product(s) : JMKX000623

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Orion Corporation

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.

                          Product Name : GV-971

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2020

                          Lead Product(s) : Sodium Oligomannate

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : This will be a randomized, double-blind, placebo-controlled and multi-center phase II Study in Relapsing-Remitting multiple sclerosis patients (RRMS). Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell lymphomas and autoimmune indica...

                          Product Name : Hibruka

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 11, 2020

                          Lead Product(s) : Orelabrutinib

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank